Abstract:Background: Iron (Fe) deficiency anemia remains the largest nutritional deficiency disorder worldwide. How the gut acquires iron from nano Fe(III), especially at the apical surface, is incompletely understood. Objective: We developed a novel Fe supplement consisting of nanoparticulate tartrate-modified Fe(III) poly oxo-hydroxide [here termed nano Fe(III)], which mimics the Fe oxide core of ferritin and effectively treats iron deficiency anemia in rats. Methods: We determined transfer to the systemic circulation of nano Fe(III) in iron-deficient and iron-sufficient outbread Swiss mouse strain (CD1) mice with use of (59)Fe-labeled material. Iron deficiency was induced before starting the Fe-supplementation period through reduction of Fe concentrations in the rodent diet. A control group of iron-sufficient mice were fed a diet with adequate Fe concentrations throughout the study. Furthermore, we conducted a hemoglobin repletion study in which iron-deficient CD1 mice were fed for 7 d a diet supplemented with ferrous sulfate (FeSO4) or nano Fe(III). Finally, we further probed the mechanism of cellular acquisition of nano Fe(III) by assessing ferritin formation, as a measure of Fe uptake and utilization, in HuTu 80 duodenal cancer cells with targeted inhibition of divalent metal transporter 1 (DMT1) and duodenal cytochrome b (DCYTB) before exposure to the supplemented iron sources. Differences in gene expression were assessed by quantitative polymerase chain reaction. Results: Absorption (means ± SEMs) of nano Fe(III) was significantly increased in iron-deficient mice (58 ± 19%) compared to iron-sufficient mice (18 ± 17%) (P = 0.0001). Supplementation of the diet with nano Fe(III) or FeSO4 significantly increased hemoglobin concentrations in iron-deficient mice (170 ± 20 g/L, P = 0.01 and 180 ± 20 g/L, P = 0.002, respectively). Hepatic hepcidin mRNA expression reflected the nonheme-iron concentrations of the liver and was also comparable for both nano Fe(III)- and FeSO4-supplemented groups, as were iron concentrations in the spleen and duodenum. Silencing of the solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 (Slc11a2) gene (DMT1) significantly inhibited ferritin formation from FeSO4 (P = 0.005) but had no effect on uptake and utilization of nano Fe(III). Inhibiting DCYTB with an antibody also had no effect on uptake and utilization of nano Fe(III) but significantly inhibited ferritin formation from ferric nitrilotriacetate chelate (Fe-NTA) (P = 0.04). Similarly, cellular ferritin formation from nano Fe(III) was unaffected by the Fe(II) chelator ferrozine, which significantly inhibited uptake and utilization from FeSO4 (P = 0.009) and Fe-NTA (P = 0.005). Conclusions: Our data strongly support direct nano Fe(III) uptake by enterocytes as an efficient mechanism of dietary iron acquisition, which may complement the known Fe(II)/DMT1 uptake pathway.

Transferrin Receptor-1 Iron-Acquisition Pathway - Synthesis, Kinetics, Thermodynamics and Rapid Cellular Internalization of a Holotransferrin-Maghemite Nanoparticle Construct.

Transferrin-Bearing Maghemite Nano-Constructs for Biomedical Applications

Apotransferrin is Internalized and Distributed in the Same Way As Holotransferrin in K562 Cells

Real-time monitoring of Ti(IV) metal ion binding of transferrin using a solid-state nanopore

Enhanced Cellular Uptake of H-Chain Human Ferritin Containing Gold Nanoparticles

Transferrin-mediated Gold Nanoparticle Cellular Uptake.

A nanoparticulate ferritin-core mimetic is well taken up by HuTu 80 duodenal cells and its absorption in mice is regulated by body iron

Transferrin-conjugated, fluorescein-loaded magnetic nanoparticles for targeted delivery across the blood–brain barrier

Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases

Maghemite Nanoparticles Coated with Human Serum Albumin: Combining Targeting by the Iron-Acquisition Pathway and Potential in Photothermal Therapies

Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway

Relative Mobility of Human Transferrin Domains Accounts for Its Efficient Recognition and Recycling

Transferrin, a Cell Pilot and Iron Provider Based on its Interaction with the Overexpressed Transferrin Receptors

Real-time Observation of the Effect of Iron on Receptor-Mediated Endocytosis of Transferrin Conjugated with Quantum Dots.

Preparation and brain targeting effects study of recombinant human ferritin nanoparticles

Ferritin: A Promising Nanoreactor and Nanocarrier for Bionanotechnology

Iron-mimic Peptide Converts Transferrin from Foe to Friend for Orally Targeting Insulin Delivery

Design and characterization of a chimeric ferritin with enhanced iron loading and transverse NMR relaxation rate

A new role for the transferrin receptor in the release of iron from transferrin

Transferrin-inspired iron delivery across the cell membrane using [(L2Fe)2(μ-O)] (L = chlorquinaldol) to harness anticancer activity of ferroptosis

Regulation mechanisms of ferric ions release from iron-loaded transferrin protein caused by nano-sized polystyrene plastics-induced conformational and structural changes